Analgesics

Analgesics is set to maintain steady current value growth in Brazil in 2023, and will remain the largest category within OTC, with a 40% share of value sales. The consumption of analgesics is mainly related to general pain, fever, and the relief of…

In late 2022 and into early 2023, a convergence of COVID-19, seasonal flu, and heightened influenza cases created what the media termed a "tripledemic," impacting Mexico, the US, and Central American nations. While Mexico did not experience the same…

Though current value sales are expected to rise, constant value sales are expected to fall, as continuing rising operating costs cut into profitability. In 2023, with concerns about COVID-19 abating, demand for analgesics reduces to more normal…

Analgesics benefitted from the era of COVID-19, as consumers sought out pain relief such as acetaminophen and ibuprofen, both of which saw extensive coverage in the media as low-cost products that could treat symptoms of the virus quickly and…

Analgesics is set to see a decline in sales in 2023 as consumers have migrated away from aspirin in an uncertain economic environment and sought to prioritise household essentials, while turning to other categories to treat basic ailments such as…

Pharmacies continue to have significant influence over the value sales of analgesics in Ecuador. For instance, in lower income neighbourhoods, pharmacies are generally stocked with generics, whereas in wealthier neighbourhoods, mainly branded…

Analgesics has not seen a positive performance in 2023 as the height of the pandemic has passed. During the pandemic’s peak, consumers were buying up analgesics at a rapid pace to treat fevers, aches and other symptoms associated with acute…

After the spike in demand for systemic analgesics in the period, 2020 to 2021, driven by COVID-19 and then by the need to relieve reactions to vaccination, in 2022 demand tended to stabilise. However, adult acetaminophen and combination analgesics…

In 2023, acetaminophen continues to lead sales of analgesics in Chile, whilst also experiencing the highest growth rate in the category. This growth has remained steady since the onset of the pandemic, where acetaminophen became the preferred choice…

While analgesics performed well during the pandemic, they has returned to more moderate growth now that the threat has subsided. In 2023, analgesics is expected to register moderate current value growth, though constant value sales are expected to…

Retail volume sales of analgesics rebounded in 2023, following a two-year period of decline. While the COVID-19 pandemic boosted demand for acetaminophen (paracetamol), which was the only analgesic recommended by the government to alleviate the…

Rising inflation has caused consumers to be increasingly stressed in 2023, with rising price points and ongoing economic uncertainty negatively impacting lives. This ongoing uncertainty has led to an increase in physical discomforts; often in the…